Protein Engineering Patents

Protein engineering patents span computational design; directed evolution; antibody engineering; and industrial enzyme biocatalysis — with major activity from biopharmaceutical companies; synthetic biology startups; and industrial biotechnology firms: MAJOR PROTEIN ENGINEERING PATENT HOLDERS: GENENTECH (ROCHE): 10,000+ biopharmaceutical patents; specific antibody engineering (specific phage display CDR library for specific affinity maturation: specific VH+VL CDR grafting onto specific human germline framework for specific humanized therapeutic antibody construction; specific YTE (M252Y/S254T/T256E) Fc engineering for specific FcRn pH-dependent half-life extension at specific specific 2-4x serum half-life improvement); REGENERON: 5,000+; specific VelocImmune (specific specific human variable region transgenic mouse for specific specific fully human antibody direct in vivo affinity maturation without specific specific humanization); specific Trap technology (specific specific VEGF Trap aflibercept; specific specific IL-6 receptor Trap); NOVOZYMES (NOVONESIS): 3,000+; specific industrial enzyme engineering (specific specific directed evolution of specific specific Bacillus sp. subtilisin protease for specific specific detergent stability at specific specific pH 10 + specific specific 60°C: specific specific error-prone PCR + specific specific DNA shuffling for specific specific variant library + specific specific automated ELISA screening; specific specific protease active site engineering for specific specific substrate specificity change); CODEX DNA (NOW TWIST BIOSCIENCE SERVICES); GENSCRIPT; IDT: 1,000+; specific gene synthesis (specific specific enzymatic DNA synthesis or specific specific column-based phosphoramidite coupling for specific specific error-free gene synthesis at specific specific cost/bp); TWIST BIOSCIENCE: 500+; specific silicon-based DNA synthesis (specific specific parallel synthesis on specific specific semiconductor chip using specific specific selective wetting for specific specific high-throughput library synthesis at specific specific cost/oligo); ARZYME (FOUNDED BY FRANCES ARNOLD CALTECH SPINOUT); ENZYME BY DESIGN; QUANTUMSI: enzyme engineering IP from directed evolution Nobel 2018.

Computational protein design; de novo protein structure generation with diffusion models; and AlphaFold-guided rational engineering represent the fastest-growing and most commercially significant patent areas in protein engineering — driven by the AI protein design revolution: COMPUTATIONAL PROTEIN DESIGN PATENTS: DAVID BAKER LAB (UNIVERSITY OF WASHINGTON; INSTITUTE FOR PROTEIN DESIGN IPD): specific Rosetta computational protein design (specific specific RosettaDesign energy function: specific specific van der Waals + specific specific electrostatic + specific specific solvation term for specific specific sequence optimization in specific specific fixed backbone template with specific specific specific measurable buried surface area + specific specific specific H-bond network criterion for specific specific thermal stability improvement vs. wild-type); specific de novo protein topology (specific specific TJ/TIM barrel design; specific specific beta-barrel; specific specific Zn-finger mimic); SPECIFIC PATENTABLE AI PROTEIN DESIGN INNOVATIONS: specific RFdiffusion (specific specific diffusion model over protein backbone atomic coordinates via specific specific denoising score matching with specific specific partial noising conditioning for specific specific target binding pocket + specific specific specific motif-scaffolding for specific specific specific functional protein generation with specific specific specific measured binding affinity Kd by specific specific specific SPR vs. specific specific specific designed target); specific ProteinMPNN (specific specific message passing neural network for specific specific inverse folding: specific specific backbone atomic coordinate → specific specific designed amino acid sequence with specific specific specific native sequence recovery rate vs. Rosetta on specific specific specific Rosetta benchmark set); specific ESMFold/OmegaFold (specific specific single-sequence language model protein structure prediction without specific specific multiple sequence alignment for specific specific specific organism-specific protein structural modeling); ALPHAFOLD-GUIDED PROTEIN ENGINEERING PATENTS: DEEPMIND/GOOGLE: specific AlphaFold2 (specific specific Evoformer: specific specific row+column self-attention applied to specific specific MSA representation for specific specific pairwise residue distance + specific specific angle distribution prediction with specific specific TM-score >0.9 on specific specific CASP14 benchmark for specific specific 98.5% of PDB structures); specific AlphaFold Multimer for specific specific protein-protein complex structure prediction; specific AlphaFold-DB 200M+ predicted structures; SPECIFIC PATENTABLE INNOVATIONS IN ALPHAFOLD-GUIDED ENGINEERING: specific structure-guided mutagenesis (specific specific AlphaFold2-predicted structure → specific specific Rosetta ddG prediction of specific specific stability-improving variant → specific specific experimental validation by specific specific DSF thermal shift assay with specific specific specific measured ΔTm improvement for specific specific specific thermostability-engineered enzyme); specific binding site prediction → specific specific inhibitor design → specific specific experimental Ki measurement.

Directed evolution; antibody CDR engineering; and industrial enzyme biocatalysis are three of the most commercially mature and IP-intensive areas of protein engineering — each with well-established patent landscapes and active ongoing innovation: DIRECTED EVOLUTION PATENTS: FRANCES ARNOLD (CALTECH); GEORGE SMITH (MIZZOU PHAGE DISPLAY); SIR GREG WINTER (MRC-LMB CAMBRIDGE ANTIBODY TECHNOLOGY): specific directed evolution methodology (specific specific Nobel Prize 2018: specific specific Arnold: specific specific random mutagenesis by specific specific error-prone PCR + specific specific DNA shuffling for specific specific directed evolution of specific specific enzyme toward specific specific substrate specificity change + specific specific stability improvement + specific specific enantioselectivity improvement with specific specific measured kcat/KM improvement on specific specific non-natural substrate at specific specific specific screening throughput per week); specific phage display (specific specific Smith filamentous M13 phage display of specific specific peptide+protein on specific specific coat protein pIII for specific specific biopanning selection vs. specific specific immobilized target; specific specific antibody phage display from specific specific naive + specific specific immune + specific specific synthetic VH+VL library for specific specific Kd <1 nM affinity selection); ANTIBODY ENGINEERING PATENTS: GENENTECH; ABBVIE; MEDAREX (BMS); REGENERON; LONZA: specific CDR grafting humanization (specific specific Kabat definition CDR regions from specific specific mouse antibody onto specific specific human germline framework for specific specific reduced immunogenicity therapeutic); specific affinity maturation (specific specific site-directed saturation mutagenesis of specific specific CDR3 residues + specific specific yeast display selection for specific specific Ka improvement); specific bispecific antibody (specific specific CrossMab CH1-CL domain swap for specific specific cognate heavy-light chain pairing in specific specific bispecific format; specific specific knobs-into-holes Fc engineering for specific specific Fc heterodimerization); specific half-life extension (specific specific YTE M252Y/S254T/T256E Fc mutation for specific specific pH-dependent FcRn binding at specific specific lysosomal pH 6 + specific specific release at specific specific neutral pH 7.4 for specific specific specific 2-4x serum t1/2); INDUSTRIAL ENZYME BIOCATALYSIS PATENTS: NOVOZYMES; DSM; DUPONT (IFF ACQUIRED); CODEXIS; BASF: specific lipase engineering (specific specific Candida antarctica lipase B CALB: specific specific directed evolution for specific specific enantioselective ester hydrolysis with specific specific specific ee >99% for specific specific pharmaceutical intermediate at specific specific specific industrial scale kg/batch); specific cellulase engineering (specific specific Trichoderma reesei cellobiohydrolase Cel7A directed evolution for specific specific thermal stability + specific specific product inhibition reduction for specific specific biofuel cellulosic ethanol application).

Protein engineering startups — at the convergence of computational design; AI; synthetic biology; and industrial biotechnology — have strong opportunities to build defensible IP around both the novel proteins themselves and the computational methods used to design them: PROTEIN ENGINEERING STARTUP IP STRATEGY: UNDERSTAND THE PROTEIN ENGINEERING IP LANDSCAPE: FOUNDATIONAL DIRECTED EVOLUTION IP: Frances Arnold Caltech directed evolution foundational patents have largely expired or are expiring; phage display Smith/Winter patents (Adalimumab/Humira phage display CAT-002 patent expired 2018) = significant whitespace opening; COMPOSITION-OF-MATTER IS STRONGEST: specific novel protein sequence with specific measured function improvement (kcat/KM; Kd; thermal stability ΔTm; enantioselectivity ee%) = highly patent-eligible composition of matter; § 101 risk is LOW for protein claims (engineered proteins = composition of matter not abstract idea); § 101 RISK FOR COMPUTATIONAL METHOD ALONE: pure AI protein design algorithm = abstract idea risk; SURVIVAL: claim the computationally designed protein sequence itself as composition of matter + claim method of making + claim measured functional result; WHAT IS PATENTABLE IN PROTEIN ENGINEERING: SPECIFIC NOVEL PROTEIN SEQUENCE WITH MEASURED FUNCTION: specific novel enzyme variant sequence (specific specific amino acid sequence having specific specific key mutations at specific specific position X+Y+Z from specific specific parent sequence) with specific measured specific specific kcat/KM improvement + specific specific specific ee% enantioselectivity + specific specific Tm thermal stability measured by specific specific DSF on specific specific substrate — composition of matter claim; SPECIFIC NOVEL ANTIBODY CDR SEQUENCE: specific novel VH+VL sequence combination with specific measured specific specific Kd to specific specific target antigen by specific specific SPR + specific specific ADCP/ADCC effector function + specific specific serum half-life; SPECIFIC NOVEL COMPUTATIONAL DESIGN METHOD: specific novel AI architecture for protein design with specific measured functional protein success rate (% designed proteins with measurable activity) on specific benchmark + specific specific measured improvement vs. prior computational design method; SPECIFIC NOVEL DIRECTED EVOLUTION PROTOCOL: specific novel screening method + specific specific selection pressure for specific specific protein function with specific specific measured throughput vs. prior FACS/ELISA approach; TRADE SECRETS: trained protein language model weights for specific organism/domain; specific active learning curriculum for specific enzyme class; specific specific high-throughput screening assay calibrated to specific production enzyme; KEY FTO: Genentech/Roche antibody humanization CDR grafting (many expired); Regeneron VelocImmune in vivo affinity maturation; Novozymes industrial enzyme directed evolution (specific family patents); Codexis/ARZYME evolved enzyme composition of matter; David Baker Lab/IPD Rosetta design + RFdiffusion (licensed exclusively vs. non-exclusively depending on application); George Smith phage display (expired 2024); Winter phage display antibody (Humira patent expired 2018); AlphaFold2 DeepMind (no broad IP restriction on using AlphaFold2 predictions to design proteins — confirmed by DeepMind model card).